Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti-ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. We took a...

詳細記述

書誌詳細

主要な著者:	Igor E. Eliseev, Valeria M. Ukrainskaya, Anna N. Yudenko, Anna D. Mikushina, Stanislav V. Shmakov, Anastasiya I. Afremova, Viktoria M. Ekimova, Anna A. Vronskaia, Nickolay A. Knyazev, Olga V. Shamova
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-08-01
シリーズ:	Biomedicines
主題:	cancer therapy monoclonal antibodies receptor tyrosine kinases HER3 antibody purification conformational stability
オンライン･アクセス:	https://www.mdpi.com/2227-9059/9/9/1106
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!